ADC drug development requires maximizing potency while minimizing off-target toxicity. Therefore, it is necessary to optimize antibodies, linkers, small molecule drugs and their reasonable combinations, which is also the core of ADC drug design. Among them, antibodies accurately deliver small molecule drugs to the tumor site by binding to antigens on the surface of tumor cells, which is one of the core factors affecting the efficacy of ADC. BOC Sciences is a leading provider of ADC development services, providing a comprehensive platform for the design, synthesis and characterization of ADCs.
BOC Sciences' ADC development platform covers a broad range of capabilities, including antibody engineering, linker chemistry, payload synthesis, conjugation chemistry, and in vitro and in vivo characterization. The platform leverages state-of-the-art technology and expertise in ADC development to efficiently and cost-effectively generate ADC drug candidates with optimized properties.
BOC Sciences provides a variety of antibody engineering services, including antibody screening, antibody modification and site-specific conjugation. Our team of experienced scientists can help customers identify and optimize monoclonal antibodies, bispecific antibodies and antibody fragments with high specificity and affinity for their target antigens, ensuring successful targeting of cancer cells.
BOC Sciences' ADC development platform includes expertise in linker chemistry, allowing the design and synthesis of a variety of cleavable linkers and non-cleavable linkers. Our linker development capabilities are extensive and technically sophisticated, including chemically labile linkers and enzymatically cleavable linkers. In addition, our platform offers customizable linker options to achieve the required stability, release kinetics, and pharmacokinetic properties of the ADC.
Our ADC platform also provides rapid access to a variety of cytotoxic payloads, as well as custom synthesis services for the development of novel payloads. BOC Sciences' expertise in organic and medicinal chemistry enables the efficient synthesis of potent and selective small molecule drugs for conjugation to antibodies.
Our platform provides expertise in conjugation chemistry, including optimization of conjugation conditions and characterization of ADC conjugates. The platform can be adapted to various conjugation strategies, such as thiol-based, amine-based and click chemistry, to ensure efficient and site-specific conjugation of payloads to antibodies.
In addition, our ADC platform provides ADC characterization and analysis services, including comprehensive in vitro and in vivo analysis services to evaluate the stability, pharmacokinetics and efficacy of ADC drug candidates. BOC Sciences scientists can perform a range of assays, including cell binding, internalization, cytotoxicity and xenograft studies, to evaluate the therapeutic potential of ADCs.
BOC Sciences can provide customers with flexible and customizable solutions to meet their specific needs. Our platform can support customers at every stage of the ADC development process, from target identification and antibody selection to preclinical and clinical development. Our ADC one-stop service platform can provide customers with a full range of ADC development support, including:
In addition to providing conventional ADC development, BOC Sciences provides one-stop support services for novel ADC therapies. We remain committed to providing high-quality, customized support for the development of novel ADC therapies and are committed to helping customers advance their innovative drug candidates from concept to clinic. Currently, our innovative ADC development capabilities cover nanobody-drug conjugates (NDCs), bispecific antibody-drug conjugates (BsADCs), degrader-antibody conjugates (DAC), antibody fragment-drug conjugates, etc.
Nanobody-drug conjugates (NDCs) are a class of therapeutic agents that combine the targeting specificity of nanobodies with the potent cytotoxic effects of drugs. By conjugating nanobodies with cytotoxic drugs, NDCs can selectively deliver drugs to the site of action, minimizing off-target effects and reducing systemic toxicity. BOC Sciences provides a variety of services for NDC development, including nanobody selection, drug conjugation, and in vitro and in vivo characterization. Our expert team has extensive experience in the design and production of bioconjugates and can provide tailor-made solutions to meet the specific needs of each project.
Bispecific antibody-drug conjugates (BsADCs) are a cutting-edge class of targeted therapeutics that hold great promise in cancer treatment. BsADCs are engineered molecules that combine antibody specificity with the cytotoxic potency of small molecule drugs. BsADCs have the potential to enhance tumor cell killing and reduce off-target toxicity compared with traditional monoclonal antibodies or ADCs. One of the key challenges in BsADC development is the design and synthesis of the complex molecular structures required to achieve the desired targeting and drug delivery properties. BOC Sciences' team of experienced chemists and biologists specializes in the design, synthesis and characterization of BsADCs, offering a full suite of services to support the development of these novel therapeutics. From initial design and selection of antibodies and drug ingredients, to synthesis and purification of the final BsADC molecule, BOC Sciences provides comprehensive support at every stage of the development process.
Degrader-antibody conjugates (DAC) are a class of bioconjugates that combine the specificity of a monoclonal antibody with the potent protein degradation activity of a small molecule degrader (DAC=PROTAC+ADC). This unique combination selectively and efficiently degrades disease-causing proteins in the body, providing a highly targeted and effective treatment. BOC Sciences' DAC services are tailored to meet the specific needs of each client, providing comprehensive services from target identification and validation to the development and optimization of DAC drug candidates. Our experienced team of scientists and researchers work closely with customers to design and execute custom DAC programs, leveraging our expertise in antibody engineering, protein degradation and drug development to deliver high-quality, reliable results.
Antibody fragment-drug conjugates (FDCs) use smaller antibody fragments (single-chain scFv) to replace larger antibody molecules. It is generally believed that antibody fragments are relatively easy to discover and bioengineering techniques can be used to achieve higher DAR. BOC Sciences offers comprehensive services for FDC development and production, from antibody selection and conjugation to in vitro and in vivo testing. Our team of experts can assist with every step of the process, from initial design and synthesis of FDCs through preclinical and clinical development.
BOC Sciences' ADC development services provide comprehensive and flexible solutions for the design, synthesis and characterization of novel ADC therapeutics. The capabilities, services and benefits of our platform enable customers to accelerate the development of high-quality ADC drug candidates with optimized properties for targeted cancer therapy. Whether customers are seeking assistance with target identification, antibody selection, custom ADC design and synthesis, or in vitro and in vivo characterization, BOC Sciences' team of experts is well-positioned to support their ADC development needs.